Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide plus lenvatinib versus lenvatinib for advanced unresectable hepatocellular carcinoma
ChiCTR2200057630Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of arsenic trioxide and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Changhai Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
arsenic trioxidelenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200057630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057630.